Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.
Avidity Biosciences (RNA) pioneers RNA-targeted therapies through its innovative Antibody Oligonucleotide Conjugate platform, addressing rare neuromuscular diseases and precision cardiology. This news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about the company’s lead programs including del-desiran for myotonic dystrophy and emerging cardiology candidates. Our curated news collection features verified press releases, earnings call analyses, and expert commentary on therapeutic advancements.
Key updates include Phase 1/2 trial results, FDA designations, intellectual property developments, and research collaborations. Bookmark this page for structured access to critical updates about RNA’s progress in delivering transformative genetic medicines.
Avidity Biosciences reported their first-quarter 2024 financial results and recent highlights, including the initiation of a global Phase 3 trial for del-desiran in DM1, positive long-term del-desiran data showing disease progression reversal in DM1 patients, and a cash position of $915 million. The company also received Breakthrough Therapy designation from the FDA for del-desiran and announced positive data from their FSHD and DMD44 trials. They raised $400 million through an equity raise and plan to share more data from ongoing trials later in the year.
Avidity Biosciences, Inc. (Nasdaq: RNA) will participate in the BofA Securities 2024 Health Care Conference on May 15. The company focuses on RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™). The event will be live-streamed and archived on the company's website.
Avidity Biosciences, Inc. (Nasdaq: RNA) has received FDA Breakthrough Therapy designation for delpacibart etedesiran (AOC 1001) for treating Myotonic Dystrophy Type 1. The company is starting a global Phase 3 HARBOR study for del-desiran this quarter. Data from MARINA-OLE showed reversal of disease progression in DM1 patients. Del-desiran aims to address the root cause of DM1, a fatal neuromuscular disease with no approved treatments.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
